Top

Published in:

01-07-2008 | Clinical Trial

Intra-hepatic Mitomycin C bolus infusion in the treatment of extensive liver metastases of breast cancer

Authors: Toon Maes, Hans Wildiers, Sam Heye, Wim Demey, Geert Maleux, Patrick Neven, Allan T. Van Oosterom, Robert Paridaens

Published in: Breast Cancer Research and Treatment | Issue 1/2008

Abstract

Background

In the treatment of extensive liver metastasis of breast cancer (LMBC), locally administered Mitomycin C (MMC) to the liver might be an effective approach with limited toxicity.

Patients and methods

We retrospectively reviewed the records of 30 patients with LMBC treated with intra-hepatic MMC at our institution. MMC (12 mg) was administered by transcatheter bolus infusion into the hepatic arteries every 4 weeks. Tumour response according to RECIST criteria, progression free survival (PFS), overall survival (OS) and duration of response (DR) were used to evaluate efficacy.

Results

There was a local response in the liver and a global response in respectively 33 and 26%. The median PFS, DR and OS were 3, 4 and 7 months, respectively. There was more benefit in patients without documented metastases outside the liver and without severe liver dysfunction. Thrombocytopenia, leucocytopenia and an allergic reaction were observed after MMC administration in 20 (67%), 12 (40%) and 4 patients (13%), respectively.

Conclusion

Intra-hepatic MMC bolus infusion as treatment of extensive LMBC is associated with limited toxicity and has a significant response rate in the liver. Prospective investigations are required to define the place of this modality for treating patients with breast cancer liver metastases.

Atalay G, Biganzoli L, Renard F et al (2003) Clinical outcome of breast cancer patients with liver metastases alone in anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials. Eur J Cancer 39:2439–2449PubMedCrossRef

Pentheroudakis G, Fountzilas G, Bafaloukos D et al (2005) Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women. Breast Cancer Res Treat 97:237–244PubMedCrossRef

Mano MS, Cassidy J, Canney P (2005) Liver metastasis from breast cancer: management of patients with significant liver dysfunction. Cancer Treat Rev 31:35–48PubMedCrossRef

Giordano SH, Buzdar AU, Smith TL et al (2004) Is breast cancer survival improving? Trends in survival for patients with recurrent breast cancer diagnosed from 1974 through 2000. Cancer 100:44–52PubMedCrossRef

Marinelli A, van De Velde CJ, Kuppen PJ et al (1990) A comparative study of isolated liver perfusion versus hepatic artery infusion with mitomycin C in rats. Br J Cancer 62:891–896PubMed

Marinelli A, Pons DH, Vreeken JA et al (1991) High mitomycin C concentration in tumour tissue can be achieved by isolated liver perfusion in rats. Cancer Chemother Pharmacol 28:109–114PubMedCrossRef

Maksan SM, Lehnert T, Bastert G, Herfarth C (2000) Curative liver resection for metastatic breast cancer. Eur J Surg Oncol 26:209–212PubMedCrossRef

Pocard M, Pouillart P, Asselain B et al (2001) Liver resections from breast cancer metastasis: results and prognosis factors after hepatic resection in 65 cases. Ann Chir 126:413–420PubMedCrossRef

Raab R, Nussbaum KT, Behrend M, Weimann A (1998) Liver metastases of breast cancer: results of liver resection. Anticancer Res 18:2231–2233PubMed

10.

Schneebaum S, Walker MJ, Young D et al (1994) The regional treatment of liver metastases from breast cancer. J Surg Oncol 55:26–31PubMedCrossRef

11.

Selzner M, Morse MA, Vredenburgh JJ et al (2000) Liver metastases from breast cancer: long-term survival after curative resection. Surgery 127:383–389PubMedCrossRef

12.

Singletary SE, Walsh G, Vauthey JN et al (2003) A role for curative surgery in the treatment of selected patients with metastatic breast cancer. Oncologist 8:241–251PubMedCrossRef

13.

Livraghi T, Goldberg SN, Solbiati L et al (2001) Percutaneous radiofrequency ablation of liver metastases from breast cancer: initial experience in 24 patients. Radiology 220:145–149PubMed

14.

Maral J, Curet P, Baumer R et al (1985) Intra-arterial chemotherapy for hepatic metastases. Experience of the Pitie-Salpetriere hospital group. Ann Gastroenterol Hepatol 21:99–101

15.

Liu LX, Zhang WH, Jiang HC et al (2002) Arterial chemotherapy of 5-fluorouracil and mitomycin C in the treatment of liver metastases of colorectal cancer. World J Gastroenterol 8:663–667PubMed

16.

Walters RS, Frye D, Buzdar AU et al (1992) A randomized trial of two doses schedules of mitomycin C in advanced breast cancer. Cancer 69:476–481PubMedCrossRef

17.

Bradner WT (2001) Mitomycin C: a clinical update. Cancer Treat Rev 27:35–50PubMedCrossRef

18.

Gadaleta C, Catino A, Mattili V (2006) Stop-flow perfusion with mitomycin-C as locoregional approach in the treatment of large-unresectable liver metastases. In Vivo 20:769–771PubMed

19.

Rump AF, Woschee U, Theisohn M et al (2002) Pharmacokinetics of intra-arterial mitomycin C in the chemoembolization treatment of liver metastases with polyvinylalcohol or degradable starch microspheres. Eur J Clin Pharmacol 58:459–465PubMedCrossRef

20.

Marinelli A, Dijkstra FR, Van Dierendonck JH et al (1991) Effectiveness of isolated liver perfusion with mitomycin C in the treatment of liver tumours of rat colorectal cancer. Br J Cancer 64:74–78PubMed

21.

Giroux MF, Baum RA, Soulen MC (2004) Chemoembolization of liver metastasis from breast carcinoma. J Vasc Interv Radiol 15:289–291PubMed

22.

Lorenz M, Hottenrot C, Seufert RM et al (1986) Continuous intravenous or intra-arterial administration via a subcutaneous implantable infusion chamber. Preliminary clinical experiences with particular reference to intra-arterial chemotherapy. Dtsch Med Wochensch 111:772–779CrossRef

23.

Onogawa S, Ito K, Nishimura K et al (1997) Liver metastases from breast cancer 14 years after radical mastectomy; successful treatment with hepatic arterial infusion chemotherapy and systemic endocrine therapy—a case report. Gan To Kagaku Ryoho 24:1804–1808PubMed

24.

Overbosch EH, Kuijpers TJ (1986) Hepatic artery bolus infusion chemotherapy with mitomycin C. Angiographic results and complications. Diagn Imaging Clin Med 55:276–281PubMed

25.

Tada A, Ogawa M, Inagaki J et al (1986) Arterial infusion of combination chemotherapy consisting of adriamycin and mitomycin C for liver metastases of breast cancer. Gan To Kagaku Ryoho 13:70–74PubMed

26.

Tokura H, Ikeda T, Kitajima M (2002) Intra-arterial infusion chemotherapy for breast cancer. Gan To Kagaku Ryoho 29:176–181PubMed

27.

Bangash AK, Atassi B, Kaklamani V et al (2007) 90Y Radioembolization of metastatic breast cancer to the liver: toxicity, imaging response, survival. J Vasc Interv Radiol 18:621–628PubMedCrossRef

28.

Oldhafer KJ, Frerker MK, Lang H et al (1998) High-dose mitomycin C in isolated hyperthermic liver perfusion for unresectable liver metastases. J Invest Surg 11:393–400PubMedCrossRef

29.

Verweij J, Pindeo HM (1990) Mitomycin C: mechanism of action, usefulness and limitations. Anticancer Drugs 1:5–13PubMedCrossRef

Title: Intra-hepatic Mitomycin C bolus infusion in the treatment of extensive liver metastases of breast cancer
Authors: Toon Maes
Hans Wildiers
Sam Heye
Wim Demey
Geert Maleux
Patrick Neven
Allan T. Van Oosterom
Robert Paridaens
Publication date: 01-07-2008
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2008
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-007-9707-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Patients and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2008

Anti-estrogenic mechanism of unliganded progesterone receptor isoform B in breast cancer cells

Concentration-dependent effects of genistein on global gene expression in MCF-7 breast cancer cells: an oligo microarray study

Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancer

Survival in breast cancer is familial

ERBB2 genetic polymorphism and breast cancer risk in Chinese women: a population-based case-control study

Cancer associated fibroblasts stimulated by transforming growth factor beta1 (TGF-β1) increase invasion rate of tumor cells: a population study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer